Cue’s CEO Ayub Khattak joins Lisa Ling on Season 2 of Johnson & Johnson’s COVID-19 Series: The Road to a Vaccine
San Diego, CA (October 20, 2020) – Cue’s CEO Ayub Khattak spoke with Lisa Ling as part of Johnson & Johnson’s The Road to a Vaccine series. During the segment, Ayub and Lisa discuss the lengthy turnaround time that many Americans have encountered during the pandemic with traditional PCR laboratory tests, and Cue’s ability to supply a highly-sensitive, molecular test that is fast, portable, and easy-to-use in point-of-care settings. Cue's recent public-private partnership with the DOD and HHS will enable the US Government to deploy 6 Million Cue COVID-19 Test to Americans, furthering access to fast, accurate molecular testing. He also notes that the company has partnered with the Biomedical Advanced Research Development Authority (BARDA), a division of HHS, since 2018 to develop a point-of-care Influenza test.
Ayub was joined by fellow panelists Dr. Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson, as well as Dr. Cato T. Laurencin, Professor at the University of Connecticut and Chief Executive Officer of the Connecticut Convergence Institute at the University of Connecticut. To view the full episode, please visit the Road to Vaccine webpage here.
About the Cue Health Monitoring System
The Cue Health Monitoring System is a portable, compact, connected diagnostic platform that provides the power of lab-quality molecular testing at point-of-care, when and where it is needed the most. The Cue Health Monitoring system works with the Cue Test Cartridge, the Cue Sample Wand, and the Cue Health App to convert test samples into accurate digital results. The single-use Cue Test Cartridge contains all the biochemistry needed to perform the molecular test. The Cue Sample Wand is a nasal swab supplied with the Cue Test Cartridge. The reusable, battery-operated Cue Cartridge Reader runs the Cue Test Cartridge and communicates results directly to the Cue Health App in about 20 minutes via a mobile smart device. The Cue Health App on the user’s mobile smart device is the user interface for test information, instructions, and display of the test results. Designed as a complete diagnostic tool, the Cue Health Monitoring System along with the Cue Test Cartridge and the Cue Health App deliver actionable health data at point-of-care.
COVID-19 Test Cartridge
The Cue COVID-19 Test Cartridge is a single-use, self-contained unit that utilizes proprietary technology to apply the reagents and associated materials required for molecular detection of the SARS-CoV-2 virus, the virus that causes COVID-19. The Cue COVID-19 Test is a high-sensitivity molecular assay that is being deployed to address urgent unmet needs in COVID-19 testing. On June 10, 2020, Cue received Emergency Use Authorization (EUA) from the US Food and Drug Administration for use of the Cue COVID-19 Test Cartridge with the Cue Health Monitoring System to detect nucleic acid from SARS-CoV-2 in nasal specimens from individuals who are suspected of COVID-19 by their healthcare provider.
About Cue Health
Cue Health Inc. (“Cue”) is an ISO 13485-certified company founded by Ayub Khattak and Clint Sever focused on developing and manufacturing professional and consumer medical diagnostic products that can be used in clinical or at-home settings. Cue’s mission is to create tools that empower healthcare providers and consumers by increasing their access to actionable health data. Cue’s first product, the Cue Health Monitoring System with the Cue COVID-19 Test Cartridge, is a platform that provides diagnostic information to clinicians and patients seeking to benefit from a connected healthcare delivery ecosystem. The company is based in San Diego, CA. For more information visit www.cuehealth.com
This test has not been FDA cleared or approved; this test has been authorized by FDA under an EUA for use by authorized laboratories; this test has been authorized only for the detection of nucleic acid from SARS CoV-2, not for any other viruses or pathogens; and this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
October 20, 2020
Stay up to date on the latest from Cue